<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03702985</url>
  </required_header>
  <id_info>
    <org_study_id>FDRT-R007</org_study_id>
    <nct_id>NCT03702985</nct_id>
  </id_info>
  <brief_title>Radiation-protection Effect of Amifostine in Locally Advanced Rectal Cancer</brief_title>
  <official_title>A Phase II Trial of Capecitabine and Irinotecan With or Without Amifostine in Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the addition of Amifostine to capecitabine and irinotecan in neoadjuvant
      chemoradiation(CRT) in locally advanced rectal cancer. Half of participants will receive
      capecitabine and along with neoadjuvant radiotherapy, followed by a cycle of XELIRI, while
      the others will receive capecitabine and irinotecan added by amifostine during CRT, followed
      by a cycle of XELIRI. All participants will be scheduled to receive surgery 6-8 weeks after
      the completion of CRT. Then it will depends which regimens the patient would receive
      according to his or her pathological results.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the morbidity of hematological adverse events and diarrhea as assessed by CTCAE v4.0</measure>
    <time_frame>during neoadjuvant chemoradiation.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of participants' quality of life during treatment as assessed by EQ-5D questionnaire and EORTC-QLQ-C30 questionnaire</measure>
    <time_frame>during neoadjuvant chemoradiation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pathological response rate</measure>
    <time_frame>Surgery scheduled 6-8 weeks after the end of chemoradiation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the morbidity of late radiation proctitis</measure>
    <time_frame>late radiation proctitis is measured 9 months after the end of chemoradiation.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Locally Advanced Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Capecitabine and Irinotecan without Amifostine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Concurrent Chemoradiotherapy:
Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7)
Chemotherapy in Interval Between CRT and Surgery:
Capecitabine: 1000mg/m2 bid d1-14; Irinotecan: 200mg/m2 d1
Surgery:
Scheduled 6-8 weeks after the completion of CRT Adjuvant Chemotherapy: depends on patients pathological review.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Capecitabine and Irinotecan with Amifostine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concurrent Chemoradiotherapy:
Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7) Amifostine: 400mg/m2 per week
Chemotherapy in Interval Between CRT and Surgery:
Capecitabine: 1000mg/m2 bid d1-14; Irinotecan: 200mg/m2 d1
Surgery:
Scheduled 6-8 weeks after the completion of CRT Adjuvant Chemotherapy: depends on patients pathological review.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>Pelvic Radiation: 50Gy/25Fx</description>
    <arm_group_label>Capecitabine and Irinotecan with Amifostine</arm_group_label>
    <arm_group_label>Capecitabine and Irinotecan without Amifostine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>625mg/m2 bid Monday-Friday per week</description>
    <arm_group_label>Capecitabine and Irinotecan with Amifostine</arm_group_label>
    <arm_group_label>Capecitabine and Irinotecan without Amifostine</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7)</description>
    <arm_group_label>Capecitabine and Irinotecan with Amifostine</arm_group_label>
    <arm_group_label>Capecitabine and Irinotecan without Amifostine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amifostine</intervention_name>
    <description>400mg/m2 per week</description>
    <arm_group_label>Capecitabine and Irinotecan with Amifostine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pathological confirmed adenocarcinoma

          -  clinical stage T3-4 and/or N+

          -  the distance from anal verge less than 12 cm

          -  without distance metastases

          -  performance status score: 0~1

          -  UGT1A1*28 6/6 or 6/7

          -  without previous anti-cancer therapy

          -  sign the inform consent

        Exclusion Criteria:

          -  pregnancy or breast-feeding women

          -  serious medical illness

          -  baseline blood and biochemical indicators do not meet the following criteria:
             neutrophils≥1.5×10^9/L, Hb≥90g/L, PLT≥100×10^9/L, ALT/AST ≤2.5 ULN, Cr≤ 1 ULN

          -  DPD deficiency

          -  UGT1A1*28 7/7
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhen Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ji Zhu, MD</last_name>
    <phone>+86-2164175590</phone>
    <phone_ext>81607</phone_ext>
    <email>leo.zhu@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji Zhu, MD</last_name>
      <email>leo.zhu@126.com</email>
    </contact>
    <investigator>
      <last_name>Zhen Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ji Zhu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>June 14, 2018</study_first_submitted>
  <study_first_submitted_qc>October 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2018</study_first_posted>
  <last_update_submitted>January 19, 2019</last_update_submitted>
  <last_update_submitted_qc>January 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zhu Ji</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Neoadjuvant Chemoradiotherapy</keyword>
  <keyword>amifostine</keyword>
  <keyword>irinotecan</keyword>
  <keyword>capecitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Amifostine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

